ACM
PTGX icon

Aster Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Aster Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-83
Closed -$5.51K – 1357
2025
Q3 		$5.51K Buy
+83
New +$4.72K ﹤0.01% 796
2025
Q2 		– Sell
-1,617
Closed -$60.8K – 1467
2025
Q1 		$60.8K Buy
+1,617
New +$67.8K 0.01% 764

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Aster Capital Management's PTGX Position: Q4 2025 in Review

Aster Capital Management sold out of Protagonist Therapeutics (PTGX) in Q4 2025, closing a stake of 83 shares — an estimated $5.51K sold.

Aster Capital Management first reported a position in PTGX in Q1 2025 and held it in 2 quarters. The position peaked at $60.8K in Q1 2025. 316 funds tracked by Wall St. Rank hold PTGX as of Q4 2025.

  • Aster Capital Management reported no remaining Protagonist Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Aster Capital Management sold 83 Protagonist Therapeutics shares in Q4 2025, an estimated $5.51K.
  • Aster Capital Management first reported a position in Protagonist Therapeutics in Q1 2025 and held it in 2 quarters.
  • Aster Capital Management's Protagonist Therapeutics position peaked at $60.8K in Q1 2025.
  • 316 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q4 2025.

Based on Aster Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.